MetaCap

Recursion Pharmaceuticals (RXRX) vs Taysha Gene Therapies (TSHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Taysha Gene Therapies (TSHA) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 11.2% versus a loss of 41.2%. Over five years, TSHA leads with a -70.7% price change compared with -87.0% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($1.53 billion vs $1.21 billion), about 1.3 times the size.

Recursion Pharmaceuticals converts more of its revenue into profit, with a net margin of -863.4% versus -1115.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RXRX-41.25%TSHA-11.22%
+72%+13%-47%
Nov 21, 20251 yearNov 20, 2026
RXRX-87.63%TSHA-72.42%
+17%-42%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RXRX versus TSHA key metrics
MetricRXRXTSHA
Share price$2.45$3.72
Market cap$1.53B$1.21B
1-day change-9.93%-1.33%
YTD return-40.10%-32.36%
1-year return-41.25%-11.22%
5-year return-87.04%-70.69%
EPS (TTM)$-0.86$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$74.68M$9.77M
Revenue growth (YoY)+26.92%+17.28%
Net income (latest FY)$-644.76M$-109.00M
Gross margin4.99%—
Operating margin-867.87%-1130.65%
Net margin-863.35%-1115.27%
52-week high$5.24$7.30
52-week low$2.44$3.46
Distance from 52-week high-53.24%-49.04%
Analyst consensusbuystrong_buy
Avg. price target upside+176.33%+249.46%
Average volume24.47M3.59M
Shares outstanding622.76M326.05M
Employees60099
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TSHA has outperformed RXRX by 30.0 percentage points over the past year.
  • Recursion Pharmaceuticals is more profitable, keeping -863.4 cents of every revenue dollar as net income versus -1115.3 cents for Taysha Gene Therapies.
  • Recursion Pharmaceuticals grew revenue faster in its latest fiscal year (+26.92% vs +17.28%).

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

About Taysha Gene Therapies

TSHA stock →

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees

RXRX vs TSHA FAQ

Which is bigger, Recursion Pharmaceuticals or Taysha Gene Therapies?

Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $1.53B compared with $1.21B for Taysha Gene Therapies (TSHA).

Which stock has performed better over the past year, RXRX or TSHA?

TSHA returned -11.22% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.

Are Recursion Pharmaceuticals and Taysha Gene Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons